Cargando…

Study of streptomycin-induced ototoxicity: protocol for a longitudinal study

Hearing impairment is due to various causes including ototoxicity from aminoglycosides. The susceptibility to aminoglycosides increases in the presence of certain mitochondria gene mutations. There is unrestrained use of aminoglycosides in many developing nations which may worsen the burden of heari...

Descripción completa

Detalles Bibliográficos
Autores principales: Adeyemo, Adebolajo A., Oluwatosin, Odunayo, Omotade, Olayemi O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912548/
https://www.ncbi.nlm.nih.gov/pubmed/27386243
http://dx.doi.org/10.1186/s40064-016-2429-5
_version_ 1782438277346754560
author Adeyemo, Adebolajo A.
Oluwatosin, Odunayo
Omotade, Olayemi O.
author_facet Adeyemo, Adebolajo A.
Oluwatosin, Odunayo
Omotade, Olayemi O.
author_sort Adeyemo, Adebolajo A.
collection PubMed
description Hearing impairment is due to various causes including ototoxicity from aminoglycosides. The susceptibility to aminoglycosides increases in the presence of certain mitochondria gene mutations. There is unrestrained use of aminoglycosides in many developing nations which may worsen the burden of hearing impairment in these countries but there is lack of data to drive required policy changes. Streptomycin (an aminoglycoside) is part of the drug regimen in re-treatment of tuberculosis. Exploring the impact of streptomycin ototoxicity in tuberculosis patients provides a unique opportunity to study aminoglycoside ototoxicity within the population thus providing data that can inform policy. Also, since streptomycin ototoxicity could adversely affect treatment adherence in tuberculosis patients this study could enable better pre-treatment counseling with subsequent better treatment adherence. Patients on tuberculosis re-treatment will be recruited longitudinally from Direct Observation Therapy-Short course centers. A baseline full audiologic assessment will be done before commencement of treatment and after completion of treatment. Early detection of ototoxicity will be determined using the American Speech and Hearing Association criteria and genetic analysis to determine relevant mitochondria gene mutations will be done. The incidence of ototoxicity in the cohort will be analyzed. Both Kaplan–Meier survival curve and Cox proportional hazards tests will be utilized to determine factors associated with development of ototoxicity and to examine association between genotype status and ototoxicity. This study will provide data on the burden and associated predictors of developing aminoglycoside induced ototoxicity. This will inform public health strategies to regulate aminoglycoside usage and optimization of treatment adherence and the management of drug-induced ototoxicity among TB patients. Furthermore the study will describe mitochondrial gene mutations associated with ototoxicity in the African population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40064-016-2429-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4912548
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-49125482016-07-06 Study of streptomycin-induced ototoxicity: protocol for a longitudinal study Adeyemo, Adebolajo A. Oluwatosin, Odunayo Omotade, Olayemi O. Springerplus Methodology Hearing impairment is due to various causes including ototoxicity from aminoglycosides. The susceptibility to aminoglycosides increases in the presence of certain mitochondria gene mutations. There is unrestrained use of aminoglycosides in many developing nations which may worsen the burden of hearing impairment in these countries but there is lack of data to drive required policy changes. Streptomycin (an aminoglycoside) is part of the drug regimen in re-treatment of tuberculosis. Exploring the impact of streptomycin ototoxicity in tuberculosis patients provides a unique opportunity to study aminoglycoside ototoxicity within the population thus providing data that can inform policy. Also, since streptomycin ototoxicity could adversely affect treatment adherence in tuberculosis patients this study could enable better pre-treatment counseling with subsequent better treatment adherence. Patients on tuberculosis re-treatment will be recruited longitudinally from Direct Observation Therapy-Short course centers. A baseline full audiologic assessment will be done before commencement of treatment and after completion of treatment. Early detection of ototoxicity will be determined using the American Speech and Hearing Association criteria and genetic analysis to determine relevant mitochondria gene mutations will be done. The incidence of ototoxicity in the cohort will be analyzed. Both Kaplan–Meier survival curve and Cox proportional hazards tests will be utilized to determine factors associated with development of ototoxicity and to examine association between genotype status and ototoxicity. This study will provide data on the burden and associated predictors of developing aminoglycoside induced ototoxicity. This will inform public health strategies to regulate aminoglycoside usage and optimization of treatment adherence and the management of drug-induced ototoxicity among TB patients. Furthermore the study will describe mitochondrial gene mutations associated with ototoxicity in the African population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40064-016-2429-5) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-06-17 /pmc/articles/PMC4912548/ /pubmed/27386243 http://dx.doi.org/10.1186/s40064-016-2429-5 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Methodology
Adeyemo, Adebolajo A.
Oluwatosin, Odunayo
Omotade, Olayemi O.
Study of streptomycin-induced ototoxicity: protocol for a longitudinal study
title Study of streptomycin-induced ototoxicity: protocol for a longitudinal study
title_full Study of streptomycin-induced ototoxicity: protocol for a longitudinal study
title_fullStr Study of streptomycin-induced ototoxicity: protocol for a longitudinal study
title_full_unstemmed Study of streptomycin-induced ototoxicity: protocol for a longitudinal study
title_short Study of streptomycin-induced ototoxicity: protocol for a longitudinal study
title_sort study of streptomycin-induced ototoxicity: protocol for a longitudinal study
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912548/
https://www.ncbi.nlm.nih.gov/pubmed/27386243
http://dx.doi.org/10.1186/s40064-016-2429-5
work_keys_str_mv AT adeyemoadebolajoa studyofstreptomycininducedototoxicityprotocolforalongitudinalstudy
AT oluwatosinodunayo studyofstreptomycininducedototoxicityprotocolforalongitudinalstudy
AT omotadeolayemio studyofstreptomycininducedototoxicityprotocolforalongitudinalstudy